1. A malignant tumor vaccine composition for mucosal administration for use in the treatment of a malignant tumor, comprising: (i) a HER2 / neu E75 peptide and / or a modified HER2 / neu E75 peptide； and (ii) a first activator of induction of cellular immunity selected from a TLR ligand, a cyclic dinucleotide, a helper peptide, an immunomodulatory low molecular weight drug, a cyclooxygenase inhibitor, a prostaglandin receptor antagonist, a prostaglandin receptor agonist, a TSLP fatty acid inhibitor, an inhibitor of an omega 3 fatty acid acid inhibitor, an inhibitor of , PPAR agonist, dopamine receptor antagonist, dopamine receptor agonist, histamine receptor agonist, histamine receptor antagonist, seroton agonist a different receptor, a serotonin receptor antagonist, a vasopressin receptor antagonist, a vasopressin receptor agonist, a muscarinic receptor antagonist, a muscarinic receptor agonist, an adrenaline receptor antagonist, an adrenaline receptor agonist, an agonist agonist receptor agonist, an agonist agonist, an agonist agonist, an agonist agonist, an agonist agonist, an agonist agonist, an agonist agonist, an agonist agonist agonist , ADP receptor agonist, leukotriene receptor antagonist, leukotriene receptor agonist, melatonin receptor agonist, ag somatostatin receptor onist, cannabinoid receptor agonist, sphingosine-1-phosphate receptor agonist, glutamate metabotropic receptor agonist, phospholipase A2 inhibitor, TGF-β production inhibitor, Th2-cytokine inhibitor, and combinations of two or more of their types. 2. The vaccine composition according to claim 1, additionally containing a second activator indu1. Вакцинная композиция против злокачественной опухоли для мукозального введения для применения в лечении злокачественной опухоли, содержащая:(i) пептид HER2/neu E75 и/или модифицированный пептид HER2/neu E75； и(ii) первый активатор индукции клеточного иммунитета, выбранный из лиганда TLR, циклического динуклеотида, хелперного пептида, иммуномодулирующе
